Ivax generic Zyprexa ruling
Executive Summary
Ivax expects a decision on its challenge of Lilly's atypical antipsychotic Zyprexa (olanzapine) by year end, the generic firm said. "Our patent challenge trial on Zyprexa concluded in February 2004, and we expect a decision before the end of the year," Ivax President Neil Flanzraich stated during a Nov. 1 earnings call. An appellate court decision invalidating a GlaxoSmithKline patent for Paxil could boost Ivax' Zyprexa case (1"The Pink Sheet" May 3, 2004, p. 18). An Ivax patent challenge of Forest's antidepressant Lexapro begins in May 2005, Flanzraich noted...